Skip to main content
. 2017 Mar 13;8(21):34736–34749. doi: 10.18632/oncotarget.16152

Figure 1. Dasatinib induced effects in wild-type FVB/N mice.

Figure 1

Wild-type animals were treated for 14 days with vehicle control (n = 10; green), 5 mg/kg (n = 8; light blue) or 20 mg/kg dasatinib (n = 9; dark blue) and the spleen and bone marrow (BM) cells were analyzed by FACS. (A) Percent of Gr1 positive granulocytes (gated on living cells), as well as percentage of lymphocytes (% gated on FCSlow/SSClow). (B) Differentiation of mature (Gr1 high/CD11b expression) and immature (Gr1 low/CD11b expression) granulocytes in BM and spleen. (C) Evaluation of the percentage of megakaryocytes (CD41+) and erythroid cells (Ter119+) in BM and spleen gated on living cells. (D) Analysis of the spleen revealed a significant loss of spleen weight after 20 mg/kg dasatinib. (E) Detailed characterization of lymphocytes by staining for B220+ (B cells), CD3, CD4 and CD8 (T cells) in BM and spleen. (F) Natural killer cells (NK cells) stained for CD49b and NK1.1 double positivity in the BM and the spleen. All data are shown as mean ± SD. *p < 0.05.